|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of CDC25B were generally higher than those of CDC25A and C. Of the 40 gastric carcinomas, 70% of the tumors expressed CDC25B mRNA at higher levels than the corresponding normal mucosas, while 38% overexpressed CDC25A mRNA.
|
9414655 |
1997 |
|
Carcinoma
|
0.050 |
GeneticVariation
|
group |
BEFREE |
The expression levels of CDC25B were generally higher than those of CDC25A and C. Of the 40 gastric carcinomas, 70% of the tumors expressed CDC25B mRNA at higher levels than the corresponding normal mucosas, while 38% overexpressed CDC25A mRNA.
|
9414655 |
1997 |
|
Lymphoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
|
Adult Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
|
Childhood Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
CD437 (1 microM) up-regulated the expression of c-Myc and of its downstream target genes ornithine decarboxylase (ODC) and cdc25A in all three NSCLC cell lines (i.e., H460, SK-MES-1 and H1792) used.
|
10445853 |
1999 |
|
Malignant neoplasm of ovary
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
|
10467347 |
1999 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
|
10467347 |
1999 |
|
Ovarian Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
|
10467347 |
1999 |
|
Acute myelomonocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hypophosphorylation of pRB and repression of cyclin D3 and cdc25A during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells.
|
10573135 |
1999 |
|
Myeloblastic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hypophosphorylation of pRB and repression of cyclin D3 and cdc25A during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells.
|
10573135 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Normal peripheral blood lymphocytes and reactive tissues expressed cdc25B1 and -B3 mRNA and very low or undetectable levels of cdc25A, -B2 and -C. High levels of cdc25A and cdc25B2 were found in 35% and 39% of the tumors, respectively, and they were more frequently observed in aggressive than in indolent lymphomas. cdc25B1 and -B3 splice variants were detected in virtually all tumors, and no significant differences were found between high- and low-grade lymphomas. cdc25A and -B protein expression was also higher in aggressive than in indolent lymphomas. cdc25C expression was relatively low in virtually all cases.
|
10754492 |
2000 |
|
Lymphoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In conclusion, these findings suggest that cdc25A and -B2, but not cdc25B1, -B3 and -C, are over-expressed in a relatively large number of malignant lymphomas and may participate in the pathogenesis of aggressive variants.
|
10754492 |
2000 |
|
Hodgkin Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.
|
10754492 |
2000 |
|
Indolent Non-Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Normal peripheral blood lymphocytes and reactive tissues expressed cdc25B1 and -B3 mRNA and very low or undetectable levels of cdc25A, -B2 and -C. High levels of cdc25A and cdc25B2 were found in 35% and 39% of the tumors, respectively, and they were more frequently observed in aggressive than in indolent lymphomas. cdc25B1 and -B3 splice variants were detected in virtually all tumors, and no significant differences were found between high- and low-grade lymphomas. cdc25A and -B protein expression was also higher in aggressive than in indolent lymphomas. cdc25C expression was relatively low in virtually all cases.
|
10754492 |
2000 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in the breast cancer cell line MCF-7, Cdc25A activity is necessary for both the activation of Cdk2 and the subsequent induction of S-phase entry.
|
10995786 |
2000 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in the breast cancer cell line MCF-7, Cdc25A activity is necessary for both the activation of Cdk2 and the subsequent induction of S-phase entry.
|
10995786 |
2000 |
|
Mammary Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
These data suggest that overexpression of Cdc25A contributes to the biological behavior of primary breast tumors and that both Cdc25A and Cdk2 are suitable therapeutic targets in early-stage breast cancer.
|
10995786 |
2000 |
|
Early-Stage Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that overexpression of Cdc25A contributes to the biological behavior of primary breast tumors and that both Cdc25A and Cdk2 are suitable therapeutic targets in early-stage breast cancer.
|
10995786 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The cdc25B2 splicing variant was detected in 27 carcinomas (79%) but only in 9 normal samples (26%) and was associated with the grade of the differentiation of the tumors. cdc25A mRNA was overexpressed in four tumors (12%) and cdc25C1 mRNA was overexpressed in nine tumors (26%).
|
11304565 |
2001 |
|
Carcinoma
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The cdc25B2 splicing variant was detected in 27 carcinomas (79%) but only in 9 normal samples (26%) and was associated with the grade of the differentiation of the tumors. cdc25A mRNA was overexpressed in four tumors (12%) and cdc25C1 mRNA was overexpressed in nine tumors (26%).
|
11304565 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |
|
Squamous cell carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
|
11487274 |
2001 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the genes identified by this method were the cell cycle-associated genes Cdc25A and c-Myc, both of which have been implicated in breast cancer.
|
12045150 |
2002 |